Body weight does not impact pregnancy rates during use of a low-dose extended-regimen 91-day oral contraceptiveWESTHOFF, Carolyn L; HAIT, Howard I; REAPE, Kathleen Z et al.Contraception (Stoneham). 2012, Vol 85, Num 3, pp 235-239, issn 0010-7824, 5 p.Article

A Randomized, Evaluator-Blind, Phase 2 Study Comparing the Safety and Efficacy of Omadacycline to Those of Linezolid for Treatment of Complicated Skin and Skin Structure InfectionsNOEL, Gary J; DRAPER, Michael P; HAIT, Howard et al.Antimicrobial agents and chemotherapy. 2012, Vol 56, Num 11, pp 5650-5654, issn 0066-4804, 5 p.Article

A phase 3, randomized, double-blind, placebo-controlled study of the safety and efficacy of the live, oral adenovirus type 4 and type 7 vaccine, in U.S. military recruitsKUSCHNER, Robert A; RUSSELL, Kevin L; QI LIU et al.Vaccine. 2013, Vol 31, Num 28, pp 2963-2971, issn 0264-410X, 9 p.Article

Endometrial microstructure after long-term use of a 91-day extended-cycle oral contraceptive regimenANDERSON, Freedolph D; HAIT, Howard; HSIU, Jeng et al.Contraception (Stoneham). 2005, Vol 71, Num 1, pp 55-59, issn 0010-7824, 5 p.Article

A Phase I and pharmacokinetic study of squalamine, a novel antiangiogenic agent, in patients with advanced cancersBHARGAVA, Pankaj; MARSHALL, John L; DAHUT, William et al.Clinical cancer research. 2001, Vol 7, Num 12, pp 3912-3919, issn 1078-0432Article